Acknowledgments
malaria, nirmatrelvir, AMD, MP
MALARIA, TROPICAL DISEASES
This study is supported by Wellcome Trust grant reference 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator.We thank all the patients with COVID-19 who volunteered to be part of the study. We thank the data safety and monitoring board (Tim Peto, André Siqueira, and Panisadee Avirutnan); the trial steering committee (Nathalie Strub-Wourgaft, Martin Llewelyn, Deborah Waller, and Attavit Asavisanu); Sompob Saralamba and Tanaphum Wichaita for developing the Rshiny randomisation app; and Mavuto Mukaka for invaluable statistical support. We also thank all the staff of the clinical trials unit at MORU, Thermo Fisher for their excellent support with this project, and all the hospital staff at the Hospital for Tropical Diseases, as well as those involved in sample processing in MORU and the processing and analysis at the Faculty of Tropical Medicine, Mahidol University, molecular genetics laboratory, and the malaria laboratory.We thank the Department of Medical Services, Ministry of Public Health, Thailand for the generous support and the donation of the molnupiravir and nirmatrelvir for this study. We thank the MORU Clinical Trials Support Group for data management, monitoring and logistics, and the purchasing, administration and support staff at MORU.
WHKS contributed to the funding acquisition, investigation, methodology, project administration, supervision, validation, and writing of the original draft. PJ contributed to the investigation, methodology, project administration, supervision, validation, and writing of the original draft. JAW contributed to the conceptualisation, data curation, formal analysis, funding acquisition, methodology, visualisation, and writing of the original draft. SB contributed to the investigation, methodology, project administration, and writing of the original draft. VL, TS, and TNga contributed to the investigation, methodology, and supervision. EMB contributed to the data curation, formal analysis, and visualisation. CC, JJC, SS, MS, VK, NT, and JT contributed to the methodology, investigation, and project administration.TNge contributed to the data curation, software, and supervision. WM, JK, KS, WPa, MYA, and NP contributed to the investigation and methodology. PH, BH, KP, and VC contributed to the investigation and supervision. MP, AS, and BL contributed to supply of trial materials. WRJT contributed to the methodology and supervision. KC and MI contributed to the formal analysis, investigation, resources, and supervision. SP, AMD, MMT, WPi, and WPh contributed to the methodology, investigation, resources, and supervision.NPJD contributed to the funding acquisition, methodology, investigation, resources, and supervision. NJW contributed to the conceptualisation, funding acquisition, methodology, supervision, validation, and writing of the original draft. All authors were involved in writing, review, and editing of the manuscript. JAW, WHKS, EMB, TNge, MI, and NJW have directly accessed and verified the underlying data reported in the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
We declare no competing interests.